

Market Announcement

5 December 2024

Paradigm Biopharmaceuticals Limited (ASX: PAR) – Trading Halt

Description

The securities of Paradigm Biopharmaceuticals Limited ('PAR') will be placed in trading halt at the request of PAR, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 9 December 2024 or when the announcement is released to the market.

Issued by

ASX Compliance



5th December, 2024

By email: melissa.kostopoulos@asx.com.au

Melissa Kostopoulos Adviser, Listings Compliance (Melbourne) ASX Limited

Dear Melissa

Request for a trading halt

Paradigm Biopharmaceuticals Limited ACN 169 346 963 (ASX: PAR) (the Company), requests that the Company's securities be placed into a trading halt with immediate effect.

For the purposes of Listing Rule 17.1, the Company provides the following information:

- 1. (a) the Company is seeking the trading halt pending an announcement in relation to a capital raising;
- 2. (b) the Company requests that the trading halt continues until the earlier of it making an announcement regarding the capital raising or until the commencement of trading on Monday 9th December 2024; and
- 3. (c) the Company is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.

Please contact us should you have any questions.

Yours faithfully

Abby Macnish Niven

Company Secretary

For and on behalf of the Board of Paradigm Biopharmaceuticals Limited

Paradigm Biopharmaceuticals Ltd

ABN: 94 169 346 963

Level 15, 500 Collins Street, Melbourne, VIC, 3000, AUSTRALIA

AUSTRALIA (Head Office) Melbourne, Victoria 3000

Paradigm Biopharmaceuticals Limited Paradigm Biopharmaceuticals (USA) Inc Paradigm Biopharmaceuticals (Ireland)

USA

IRELAND Limited Fitzwilliam Hall, Fitzwilliam Place Dublin 2

